SingleSexual & Hormonal

Triptorelin 2mg

Potent synthetic GnRH agonist evaluated for its biphasic endocrine profile, producing an initial gonadotropin surge followed by axis shutdown.

Mechanism

Binds continuously with high affinity to pituitary GnRH receptors, triggering an initial gonadotropin surge that is rapidly followed by profound receptor desensitization and down-regulation to arrest downstream sex steroid production.

Dosing

Standard laboratory reference conversions document an initial benchmark amount of 0.1 mg for experimental concentration modeling.

Reconstitution

Reconstituting a 2 mg vial with 2 mL of bacteriostatic water yields a standard research concentration of 1 mg/mL.

Storage

Store the lyophilized vial in a cool, light-shielded area, and preserve the reconstituted liquid at 2–8 °C without freezing.

Mix & measure Triptorelin 2mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Triptorelin 2mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration1.00mg/mL

Draw volume0.100mL

On the syringe10.0units

Total doses in vial: 20.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Low Reference	0.1 mg (laboratory metric)	10 units (0.10 mL)
Moderate Reference	0.5 mg (laboratory metric)	50 units (0.50 mL)
High Reference	1.0 mg (laboratory metric)	100 units (1.00 mL)
Full Vial Reference	2.0 mg (laboratory metric)	200 units (2.00 mL)

Reconstitution Steps

1
Thoroughly clean the rubber septums of both the peptide vial and the diluent vial using sterile alcohol prep pads, allowing them to dry fully.
2
Draw precisely 2 mL of bacteriostatic water into a sterile syringe.
3
Insert the needle into the peptide vial at an angle, directing the stream against the interior glass wall to avoid direct turbulence onto the lyophilized cake.
4
Allow the vial to rest undisturbed for 30 seconds to initiate passive dissolution.
5
Gently rotate and roll the container between your palms until the solution becomes completely clear; do not shake or agitate forcefully.
6
Transfer the dissolved solution into refrigeration at 2–8 °C, shielded from light exposure.

Supplies Needed

Peptide Vial

Lyophilized active research sample requiring dilution

Insulin Syringes (U-100)

Precision measuring tool for accurate volume micro-dispensation

Bacteriostatic Water

Sterile diluent with preservative used to reconstitute the peptide

Alcohol Swabs

Sanitization of vial stoppers and tools before sampling

Why researchers study it

Testosterone & the HPTA

Prostate cancer & endometriosis

The initial flare

Fertility & puberty

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Triptorelin acetate is a synthetic decapeptide analogue of natural gonadotropin-releasing hormone (GnRH). In physiological systems, endogenous GnRH is released from the hypothalamus in discrete pulsatile bursts to stimulate pituitary gonadotropin release. In contrast, triptorelin exhibits sustained and high-affinity receptor occupancy, completely altering the signaling dynamics of the hypothalamic-pituitary-gonadal axis. The pharmacodynamic profile of triptorelin is distinctly biphasic. Initial application triggers rapid release of luteinizing hormone and follicle-stimulating hormone, producing a transient hormonal flare. With prolonged and uninterrupted exposure, the pituitary receptors desensitize and down-regulate, precipitating a collapse in gonadotropin release that reduces sex steroids to castrate or menopausal baselines. In scientific literature, clinical formulations rely on microsphere-based sustained-release depots for managing androgen-dependent prostate carcinomas, endometriosis, and precocious puberty. In laboratory research contexts, lyophilized research vials serve as analytical standards for studying GnRH receptor kinetics, receptor desensitization pathways, and downstream endocrine cascade modulations.

References

1.Romero et al., Journal of Pharmacology and Experimental Therapeutics, 2012 — PK/PD model of the testosterone effects of triptorelin in sustained-release formulations in prostate cancer
2.Msaouel et al., Expert Opinion on Emerging Drugs, 2007 — Luteinising hormone-releasing hormone antagonists in prostate cancer therapy
3.Damber et al., Urology, 2012 — Effect of baseline testosterone on the efficacy of degarelix and leuprolide: phase III study
4.Li et al., Chinese Journal of Surgery, 2008 — Efficacy and safety of long-acting triptorelin in metastatic prostate cancer